

Supplemental Online Content

Wu H, Shi J, Luo Y, et al. Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation. *JAMA Netw Open*. 2021;4(1):e2034750. doi:10.1001/jamanetworkopen.2020.34750

eTable. Safety Profile of Ruxolitinib

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable. Safety Profile of Ruxolitinib

Adverse effects	Cases (%)
Infection	
Lung infection	11/41(26.8)
CMV reactivation	5/34(14.7)
EBV reactivation	19/36(52.7)
Sepsis	2/41(4.9)
HBV reaction	1/41(2.4)
Cytopenia	6/41(14.6)
Grade 1-2	3(7.3)
Grade 3-4	3 (7.3)
Malignancy relapse	6/41(14.6)
Necrosis of femoral head	8/41(19.5)

Abbreviations: CMV, Cytomegalovirus; EBV, Epstein-Barr virus; HBV, hepatitis B virus.